Annual Financials for ICU Medical Inc.
Fiscal year is January-December. All values USD millions. |
2017 | 2018 | 2019 | 2020 | 2021 |
5-year trend |
Sales/Revenue
|
1.29B | 1.4B | 1.27B | 1.27B | 1.32B | |
Sales Growth |
- | 8.31% | -9.56% | 0.38% | 3.56% | |
Cost of Goods Sold (COGS) incl. D&A |
867.4M | 830.76M | 795.26M | 810.3M | 837.86M | |
COGS excluding D&A |
800.83M | 756.02M | 710.05M | 715.45M | 738.56M | |
Depreciation & Amortization Expense |
66.57M | 74.74M | 85.21M | 94.85M | 99.29M | |
Depreciation |
51.57M | 58.14M | 67.51M | 71.65M | 75.49M | |
Amortization of Intangibles |
15M | 16.6M | 17.7M | 23.2M | 23.8M | |
COGS Growth |
- | -4.23% | -4.27% | 1.89% | 3.40% | |
Gross Income |
425.21M | 569.29M | 470.95M | 460.71M | 478.45M | |
Gross Income Growth |
- | 33.88% | -17.27% | -2.17% | 3.85% | |
Gross Profit Margin |
- | - | - | - | 36.35% | NA |
|
2017 | 2018 | 2019 | 2020 | 2021 |
5-year trend |
SG&A Expense |
355.21M | 373.11M | 325.59M | 326.9M | 340.49M | |
Research & Development |
51.25M | 52.87M | 48.61M | 42.95M | 47.5M | |
Other SG&A |
303.95M | 320.25M | 276.98M | 283.95M | - | |
SGA Growth |
- | 5.04% | -12.74% | 0.40% | 4.16% | |
Other Operating Expense |
- | - | - | - | - | |
Unusual Expense |
85.97M | 167.4M | 38.91M | 36.43M | 18.16M | |
EBIT after Unusual Expense |
(15.96M) | 28.77M | 106.44M | 97.37M | 119.8M | |
Non Operating Income/Expense |
69.29M | (11.06M) | 2.01M | (1.83M) | 1.57M | |
Non-Operating Interest Income |
- | 5.37M | 6.8M | 3.7M | 2.8M | |
Equity in Affiliates (Pretax) |
- | - | - | - | - | |
Interest Expense |
2.05M | 709,000 | 549,000 | 1.75M | 980,000 | |
Interest Expense Growth |
- | -65.36% | -22.57% | 219.31% | -44.10% | |
Gross Interest Expense |
2.05M | 709,000 | 549,000 | 1.75M | 980,000 | |
Interest Capitalized |
- | - | - | - | - | |
Pretax Income |
51.28M | 22.37M | 114.71M | 97.49M | 123.19M | |
Pretax Income Growth |
- | -56.37% | 412.68% | -15.01% | 26.35% | |
Pretax Margin |
- | - | - | - | 9.36% | NA |
Income Tax |
(17.36M) | (6.42M) | 13.67M | 10.62M | 20.05M | |
Income Tax - Current Domestic |
5.04M | 2.36M | 9.38M | 8.45M | 24.09M | |
Income Tax - Current Foreign |
3.17M | 9.14M | 7.99M | 7.29M | 7.24M | |
Income Tax - Deferred Domestic |
(25.5M) | (12.19M) | (7.05M) | (7.17M) | (9.97M) | |
Income Tax - Deferred Foreign |
(71,000) | (5.72M) | 3.34M | 2.05M | (1.31M) | |
Income Tax Credits |
- | - | - | - | - | |
Equity in Affiliates |
- | - | - | - | - | |
Other After Tax Income (Expense) |
- | - | - | - | - | |
Consolidated Net Income |
68.64M | 28.79M | 101.04M | 86.87M | 103.14M | |
Minority Interest Expense |
- | - | - | - | - | |
Net Income |
68.64M | 28.79M | 101.04M | 86.87M | 103.14M | |
Net Income Growth |
- | -58.05% | 250.90% | -14.02% | 18.72% | |
Net Margin Growth |
- | - | - | - | 7.84% | NA |
Extraordinaries & Discontinued Operations |
- | - | - | - | - | |
Extra Items & Gain/Loss Sale Of Assets |
- | - | - | - | - | |
Cumulative Effect - Accounting Chg |
- | - | - | - | - | |
Discontinued Operations |
- | - | - | - | - | |
Net Income After Extraordinaries |
68.64M | 28.79M | 101.04M | 86.87M | 103.14M | |
Preferred Dividends |
- | - | - | - | - | |
Net Income Available to Common |
68.64M | 28.79M | 101.04M | 86.87M | 103.14M | |
EPS (Basic) |
3.50 | 1.41 | 4.90 | 4.16 | 4.86 | |
EPS (Basic) Growth |
- | -59.66% | 246.91% | -15.16% | 17.05% | |
Basic Shares Outstanding |
19.61M | 20.39M | 20.63M | 20.91M | 21.21M | |
EPS (Diluted) |
3.29 | 1.33 | 4.69 | 4.02 | 4.74 | |
EPS (Diluted) Growth |
- | -59.48% | 251.80% | -14.20% | 17.69% | |
Diluted Shares Outstanding |
20.86M | 21.6M | 21.55M | 21.59M | 21.78M | |
EBITDA |
136.57M | 270.91M | 230.57M | 228.65M | 237.26M | |
EBITDA Growth |
- | 98.36% | -14.89% | -0.83% | 3.76% | |
EBITDA Margin |
- | - | - | - | 18.02% | NA |